The biotech sector is experiencing a genuine recovery despite persistent market skepticism. While investor sentiment remains cautious, underlying industry metrics show substantial improvement in drug development pipelines, regulatory approvals, and clinical trial success rates. This analysis identifies three undervalued biotech companies currently trading at significant discounts to their historical valuations, positioning them as potential leaders as the sector gains broader market recognition and institutional investment returns.

Summary auto-generated by AI from the original publisher's content. Editorial standards.